Therapeutic Exploratory (Phase II)

3,454 trials 1,368 recruiting

Filter these 3,454 trials by condition, country, sponsor and more.

Open in Search →

Ribociclib in combination with endocrine therapy in patients with “estrogen receptor-positive and HER2-negative” breast cancer with high ris… Ended

2023-508827-10-00 Patients with primary operable stage II, grade 2 or 3, 2025-10-13
A Study Evaluating Monthly (Every 4 Weeks) Dosing of Atacicept in Patients with IgAN Ended

2025-521519-37-00 IgA Nephropathy (IgAN); Berger Disease; Renal and Urina 2025-10-10
Study of zoldonrasib in Previously Treated Patients with RAS G12D-Mutant Non-Small Cell Lung Cancer (NSCLC) Ended

2025-521681-10-00 Lung Cancer 2025-10-02
A Study to Test Inavolisib Treatments in Patients with Early-Stage, PIK3CA-Mutated Breast Cancer Ended

2024-518811-20-00 Early-Stage, PIK3CA-Mutated Breast Cancer (BC) 2025-09-30
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer Ended

2025-521115-40-00 Advanced or Metastatic Non-small Cell Lung Cancer 2025-09-30
A Study to Compare Different Doses of RO7795081 with a Placebo or Semaglutide in People with Type 2 Diabetes Ended

2024-520322-11-00 Type 2 Diabetes Mellitus (T2D) 2025-09-29
Trial of Sibeprenlimab in the Treatment of Sjögren’s Disease Ended

2024-516295-14-00 Treatment of Sjögren’s disease 2025-09-17
Safety and Impact of Baricitinib on Cell Surivival Pathways, HIV-1 Reservoir and Inflamation in People With HIV-1 Ended

2024-520159-26-00 Human immunodeficency virus 2025-09-17
Study to assess whether Verekitug can improve the control of Chronic Obstructive Pulmonary Disease (COPD) Ended

2025-520488-42-00 Moderate-to-Severe Chronic Obstructive Pulmonary Diseas 2025-09-17
Study of BLU-808 in Chronic Inducible Urticaria and Chronic Spontaneous Urticaria Ended

2024-520031-33-00 Chronic Inducible Urticaria and Chronic Spontaneous Urt 2025-09-16
A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease Ended

2024-519746-70-01 Sickle Cell Disease 2025-09-15
A study to test whether vicadrostat in combination with empagliflozin helps people with chronic kidney disease Ended

2024-518457-42-00 chronic kidney disease 2025-08-28
A Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults with Celiac Disease Ended

2024-517081-42-00 Celiac Disease 2025-08-15
Proof of Concept trial with CIT-013 in Rheumatoid Arthritis Ended

2024-517356-35-00 Moderately Active Rheumatoid Arthritis 2025-07-29
Rezafungin for treatment of chronic pulmonary aspergillosis (CPA) in adults with limited treatment options Ended

2024-519575-26-00 Chronic pulmonary aspergillosis (CPA) 2025-07-25
A Study to Evaluate Tobevibart+Elebsiran versus Bulevirtide in Chronic HDV Infection Ended

2024-520062-54-00 Chronic Hepatitis D Virus (HDV) Infection 2025-07-23
A Study of ABBV-CLS-628 in Adult Subjects with Autosomal Dominant Polycystic Kidney Disease Ended

2024-517143-31-00 Autosomal Dominant Polycystic Kidney Disease 2025-07-18
A study to assess the efficacy and safety of ITI-1284 in the treatment of Agitation Associated with Alzheimer's Dementia Ended

2024-514680-26-00 Agitation Associated with Alzheimer’s Dementia 2025-07-17
Leniolisib for immune dysregulation in CVID Ended

2024-517725-93-00 Common variable immunodeficiency 2025-07-14
A Phase 2b Study to Assess IMVT-1402 in Participants with Cutaneous Lupus Erythematosus Ended

2024-516745-39-00 Cutaneous lupus erythematosus 2025-07-11
A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants with PMM2-CDG Ended

2024-520109-37-00 PMM2-CDG 2025-07-09
A Phase 2 Study of CAL101 in Patients with Idiopathic Pulmonary Fibrosis Ended

2024-518339-12-00 Idiopathic Pulmonary Fibrosis 2025-07-08
A Trial to Study the Safety and Efficacy of a New Drug Combination for Weight Loss While Maintaining Muscles Ended

2024-519561-22-00 Obesity 2025-07-07
A Phase 2, open-label study to evaluate the efficacy and safety of anitocabtagene autoleucel in participants with newly diagnosed multiple m… Ended

2024-517020-18-00 Newly diagnosed multiple myeloma according to IMWG cri 2025-06-30